title: Induction by Lactobacillus casei of increase in macrophage colony-forming cells and serum colony-stimulating activity in mice.
abstract: The content of macrophage colony-forming cells (M-CFC) and the serum colony-stimulating activity (CSA) were investigated in mice after intravenous administration of Lactobacillus casei YIT9018 (LC9018). In normal BALB/c mice, 500 micrograms of LC9018 increased both femoral and splenic M-CFC; the highest levels were found a few days and a week, respectively, after the administration. LC9018 also induced an increase in splenic M-CFC in C3H/HeJ mice as well as in C3H/HeN mice, unlike lipopolysaccharide (LPS), which was ineffective in C3H/HeJ mice. In Meth A-bearing BALB/c mice, LC9018 (250 micrograms X 5) suppressed the growth of tumor cells and increased femoral and splenic M-CFC to much greater extents than Lactobacillus plantarum YIT0102 (250 micrograms X 5) did. LC9018 induced a rise of serum granulocyte-macrophage CSA in the same way as LPS. Sera taken 6 hr after LPS administration, when transferred to normal mice, induced increases in femoral and splenic M-CFC. However, sera taken 6 hr after LC9018 administration increased neither femoral nor splenic M-CFC. These results indicate that LC9018 modulates myelopoiesis at least at the stage of the proliferation of M-CFC in a different way from LPS, and this ability may be related to its antitumor activity.
mesh_terms: D000818:Animals; D001853:Bone Marrow / Q000502:physiology; D003114:Colony-Forming Units Assay; D003115:Colony-Stimulating Factors / Q000502:physiology*; D006410:Hematopoiesis; D007167:Immunotherapy; D007780:Lacticaseibacillus casei / Q000276:immunology*; D008262:Macrophage Activation; D008264:Macrophages / Q000502:physiology*; D051379:Mice; D009374:Neoplasms, Experimental / Q000628:therapy; D013154:Spleen / Q000502:physiology; D013997:Time Factors
chemical_list: D003115:Colony-Stimulating Factors